Pfizer gets US contract for 50m COVID-19 vaccine doses for kids

By
Reuters
|
Vials labelled COVID-19 Coronavirus Vaccine and a syringe are seen in front of the Pfizer logo in this illustration taken February 9, 2021. — Reuters/File
Vials labelled "COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Pfizer logo in this illustration taken February 9, 2021. — Reuters/File
  • Move comes after a panel of outside advisers voted to recommend its authorisation for the vaccine in children aged 5 to 11.
  • The US government has so far secured 600 million doses of the vaccine for use.
  • The drugmakers say they expect initial clinical trial data on the vaccine's use in children to take place in the fourth quarter this year.


Pfizer Inc and BioNTech SE said on Thursday they expect to deliver 50 million more doses of their COVID-19 vaccine to the US government by April-end, as the country prepares to vaccinate children.

The move comes after a panel of outside advisers to the US Food and Drug Administration voted on Tuesday to recommend its authorisation for the vaccine in children aged 5 to 11. The agency's decision on the vaccine for the age group is awaited.

If authorised and subsequently recommended by the US Centers for Disease Control and Prevention's (CDC) advisory panel, the companies said they expect to then begin shipping the vaccine immediately, in 10 microgram pediatric doses, as directed by the US government.

The US government has so far secured 600 million doses of the vaccine for use within the country and additional one billion doses for donation to low- and lower-middle-income countries.

The drugmakers said they expect initial clinical trial data on the vaccine's use in children — aged 2 to less than 5 years, and 6 months to less than 2 years — to take place in the fourth quarter this year or early first quarter of 2022.